SCYNEXIS (SCYX) AI Stock Analysis

• Market Cap: $30.28M
• Dividend Yield: N/A
• Average Volume (3M): 105.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: -98.13%
• EPS Growth: -129.06%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.11
• Shares Outstanding: 39,020,275
• 10 Day Avg. Volume: 151,187
• 30 Day Avg. Volume: 105,709
• PEG Ratio: 0.05
• Price to Book (P/B): 0.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.12
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: 1.08
• Enterprise Value/Gross Profit: 11.11
• Enterprise Value/Ebitda: -0.18
• 1Y Price Target: $4.50
• Price Target Upside: 476.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 43 Neutral
• Price Target: $1.00 ▲( 28.21% Upside)

SCYNEXIS is currently facing significant financial and operational challenges, as reflected in its financial performance and technical indicators. The company's negative earnings and unattractive valuation metrics further contribute to a low overall stock score. Improvements in operational efficiency and cash flow generation are crucial for enhancing the company's financial health.

Positive Factors

Financial Strength

Scynexis has sufficient capital to reach milestones with $75M in cash, providing a financial runway into mid-2026.

Product Approval

Brexafemme, the first-in-class triterpenoid antifungal, has broad-spectrum fungicidal activity and is approved for vulvovaginal candidiasis.

Regulatory Progress

The FDA clinical hold on the P3 MARIO study of Brexafemme has been lifted, allowing Synexis to resume the study.

Negative Factors

Partnership Termination

GSK has notified Scynexis of its intent to terminate the agreement tied to a $30M milestone upon study resumption.

Price Target Reduction

Lowering the 12-month price target to $4.00, from $8.00, due to ongoing uncertainty with GSK on manufacturing issues related to Brexafemme commercialization.

Revenue Risk

Uncertainty around the timelines for Brexafemme commercial royalties and GSK's potential filing for approval in invasive fungal infections increases the revenue risk adjustment to 50%.

SCYNEXIS Business Overview & Revenue Model

Company Description

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

How the Company Makes Money

SCYNEXIS generates revenue primarily through the sale and licensing of its proprietary antifungal medications, particularly ibrexafungerp. The company earns money by commercializing its products in partnership with other pharmaceutical companies and through direct sales in markets where it holds regulatory approval. SCYNEXIS may also receive milestone payments, royalties, and upfront fees from strategic collaborations and licensing agreements with other firms seeking to develop and distribute its antifungal therapies in various regions. Additionally, the company might engage in research and development collaborations that could provide financial support through grants or co-development agreements.

SCYNEXIS Financial Statement Overview

Summary

SCYNEXIS faces multiple financial challenges with declining revenue and profitability, a moderately leveraged balance sheet, and negative cash flow trends. The company needs to address its operational inefficiencies and improve its cash flow to enhance financial stability.

Income Statement

SCYNEXIS shows significant volatility in its revenue and profitability. The revenue decreased sharply in 2024 from the previous year, and the company experienced a substantial net loss. The EBIT and EBITDA margins are negative, indicating operational challenges.

Balance Sheet

The company's balance sheet reflects a moderate debt-to-equity ratio and relatively stable stockholders' equity. However, the equity ratio is low, suggesting a higher reliance on liabilities, which could be risky.

Cash Flow

The cash flow situation is concerning, with negative free cash flow and operating cash flow. The company has not been able to generate positive cash flow from its operations, indicating a potential liquidity issue.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.37M	3.75M	140.14M	5.09M	13.16M	0.00
	Gross Profit
2.37M	3.75M	124.52M	4.46M	12.85M	-303.00K
	EBIT
-36.22M	-37.12M	72.67M	-85.76M	-60.83M	-51.15M
	EBITDA
-29.18M	-18.58M	73.48M	-59.91M	-31.41M	-51.15M
	Net Income Common Stockholders
-27.09M	-21.29M	67.04M	-62.81M	-32.87M	-55.19M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
40.61M	59.30M	74.36M	73.50M	104.48M	93.04M
	Total Assets
67.92M	90.64M	128.41M	87.81M	119.84M	102.54M
	Total Debt
2.49M	16.27M	15.08M	48.60M	43.63M	19.84M
	Net Debt
-4.46M	219.00K	-18.97M	2.78M	-60.86M	-73.20M
	Total Liabilities
17.38M	35.57M	55.45M	84.58M	78.58M	79.78M
	Stockholders Equity
50.53M	55.08M	72.96M	3.23M	41.26M	22.76M
Cash Flow		Free Cash Flow
-27.47M	-24.01M	60.16M	-79.89M	-55.73M	-49.36M
	Operating Cash Flow
-27.47M	-24.01M	60.16M	-79.88M	-54.56M	-49.35M
	Investing Cash Flow
13.14M	6.15M	-34.88M	-27.39M	-1.17M	6.47M
	Financing Cash Flow
-14.21M	-139.00K	-36.72M	48.60M	67.12M	94.00M

SCYNEXIS Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCYX, the sentiment is Negative. The current price of 0.78 is below the 20-day moving average (MA) of 0.92, below the 50-day MA of 0.94, and below the 200-day MA of 1.21, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 36.15 is Neutral, neither overbought nor oversold. The STOCH value of 9.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCYX.

SCYNEXIS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMTI	55 Neutral	$33.47M	―	-2.12%	―	12.82%	96.46%
Sector *	53 Neutral	$5.14B	3.03	-44.09%	2.83%	16.75%	-0.06%
DRRX	46 Neutral	$16.89M	―	-203.11%	―	-41.45%	40.69%
SCYX	43 Neutral	$30.28M	―	-43.47%	―	-98.13%	-129.06%
CPHI	37 Underperform	$7.24M	―	-59.14%	―	-33.10%	71.37%
KALA	31 Underperform	$26.07M	―	-576.46%	―	―	38.50%
SXTC		$40.34M	0.57	57.63%	―	―	―